p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples